Related Experiment Videos
[Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields]
Insights
Cefpodoxime proxetil (CPDX-PR) demonstrated high clinical efficacy and a favorable safety profile in pediatric infectious disease treatment. This new antibiotic showed significant effectiveness across various infections, with minimal adverse effects reported in clinical trials.
Area of Science:
- Pediatric infectious diseases
- Antibiotic pharmacokinetics and efficacy
- Clinical pharmacology
Background:
- Cefpodoxime proxetil (CPDX-PR) is a newly developed antibiotic.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose of the Study:
- To investigate the pharmacokinetics, clinical efficacy, and safety of cefpodoxime proxetil (CPDX-PR) in pediatric patients.
- To evaluate the effectiveness of CPDX-PR in treating various common pediatric infections.
Main Methods:
- Pharmacokinetic analysis of CPDX-PR in pediatric subjects at different dosages.
- Clinical efficacy assessment in 748 pediatric cases with diverse infectious diseases.
- Safety evaluation, including side effects and clinical laboratory findings, in 779 pediatric patients.
Main Results:
- Peak blood levels of cefpodoxime (CPDX) were dose-dependent, with lower levels observed after meals.
- High clinical efficacy rates were observed across various infections, including tonsillitis (96.8%), UTI (96.0%), and pneumonia (93.5%).
- Bacteriological eradication rates were high for both Gram-positive (91.0%) and Gram-negative (89.7%) organisms, with an 88.1% efficacy in antibiotic-resistant cases.
Conclusions:
- Cefpodoxime proxetil (CPDX-PR) exhibits favorable pharmacokinetic properties and high clinical efficacy in treating pediatric infectious diseases.
- The antibiotic demonstrated a good safety profile with a low incidence of mild side effects.
- CPDX-PR is a promising therapeutic option for pediatric infections, including those resistant to previous antibiotic treatments.
Abstract:
Dry syrup and tablet of newly developed cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24 +/- 0.21 and 4.68 +/- 0.54 micrograms/ml, respectively, in fasting and 1.65 +/- 0.07 and 3.71 +/- 0.41 micrograms/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2 +/- 2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarler fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.